Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Depotech(depo) -- Ignore unavailable to you. Want to Upgrade?

To: seminole who wrote (600)	12/19/1997 12:54:00 PM
From: Valery Portnov	Respond to of 887

DEPO sounds like BICO

To: seminole who wrote (600)	12/19/1997 1:06:00 PM
From: Czechsinthemail	Read Replies (1) \| Respond to of 887

richard, The company addressed the data question. As has been mentioned it was based on a discrepancy between "evaluable" and "intent to treat" differences. On an "evaluable" basis, they showed improvement. The real problem, I think, was small numbers that couldn't establish statistical significance. Had they had larger numbers in the study, they feel they could have established their case. I got the sense they felt the ODAC committee had reneged somewhat on an agreement with the FDA to accept small numbers, use the evaluable cases rather than intent to treat, and consider the overall improvement profile because it is a life threatening disease. My sense is that there is a good chance they will get approval with a supplemental submission of data. They also indicated that the results of their other DepoCyt studies-- lymphoma & leukemia -- were stronger. At this point I think the risk/reward situation is tilted heavily toward the reward side. All the negatives are pretty much factored in, but few of the positives. The chances of doubling or perhaps tripling the share price from here on any good news -- a new partnering announcement, plans to submit additional data to the FDA, good DepoMorphine results, etc.--seem good. The combination of bad news and a bad market day has probably combined to do about as much damage to the price of DEPO shares as we're likely to see, especially given the visibility of silver linings. Baird